Experimental testing of chemoresistance of ovarian cancer tumor cells

Cover Page

Cite item

Full Text

Abstract

One of the most challenging issues in the treatment of ovarian cancer is the high level of tumor cell chemoresistance, which leads to early tumor recurrence and low overall survival. In the case of tumor cell chemoresistance, the therapy is ineffective, resulting in unnecessary drug consumption and harm to the patient due to toxic side effects and time losses during its implementation. One approach to solving this problem is experimental predictive testing of tumor cell chemoresistance in vitro.
Aim. To develop a protocol of experimental testing of chemoresistance of ovarian cancer cells to chemotherapy drugs. We analyzed changes in the number of viable cells of A-1847, Ovcar-3 and Ovcar-4 cell lines cultured in hypo-adhesive conditions and optimized a method of cell viability determination based on resazurin metabolism. It was shown that viability of ovarian cancer cells of the studied cell lines is approximately the same in the presence of 1st and 2nd line antitumor drugs measured in accordance with the developed culture protocol in hypo-adhesive conditions and using ATP-tumor chemosensitivity assay (ATP-TCA) (DCS Innovative Diagnostik-Systeme, Germany) approved for use in clinical practice. The developed method is based on readily available and inexpensive reagents and expendables which makes it economically attractive.

About the authors

K. A. Kuzin

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: kuzin_konstantin@mail.ru
ORCID iD: 0000-0001-8474-8195

Konstantin Alexandrovich Kuzin

24 Kashirskoe Shosse, Moscow 115522, Russia

Russian Federation

T. I. Fetisov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Peoples’ Friendship University of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-5082-9883

24 Kashirskoe Shosse, Moscow 115522, Russia; 6 Miklukho-Maklaya St., Moscow 117198, Russia

Russian Federation

O. A. Vlasova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-1498-849X

24 Kashirskoe Shosse, Moscow 115522, Russia

Russian Federation

R. I. Knyazev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-6341-0897

24 Kashirskoe Shosse, Moscow 115522, Russia; 2/1 Barricadnaya St., 123995 Moscow, Russia

Russian Federation

E. E. Antoshina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru

24 Kashirskoe Shosse, Moscow 115522, Russia

Russian Federation

L. S. Trukhanova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru

24 Kashirskoe Shosse, Moscow 115522, Russia

Russian Federation

T. G. Gor’kova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru

24 Kashirskoe Shosse, Moscow 115522, Russia

Russian Federation

G. A. Belitsky

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-3167-7204

24 Kashirskoe Shosse, Moscow 115522, Russia

Russian Federation

M. G. Yakubovskaya

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Peoples’ Friendship University of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-9710-8178

24 Kashirskoe Shosse, Moscow 115522, Russia; 6 Miklukho-Maklaya St., Moscow 117198, Russia

Russian Federation

K. I. Kirsanov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Peoples’ Friendship University of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-8599-6833

24 Kashirskoe Shosse, Moscow 115522, Russia; 6 Miklukho-Maklaya St., Moscow 117198, Russia

Russian Federation

References

  1. Malignant neoplasms in Russia in 2023 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 276 p. (In Russ.).
  2. Siegel R.L., Kratzer T.B., Giaquinto A.N. et al. Cancer statistics, 2025. CA Cancer J Clin 2025;75(1):10–45. doi: 10.3322/caac.21871
  3. Pokataev I.A., Dudina I.A., Kolomiets L.A. et al. Ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. Zlokachestvennye opukholi = Malignant Tumors 2024;14(3s2–2):82–101. doi: 10.18027/2224-5057-2024-14-3s2-1.2-02
  4. Ledermann J.A., Matias-Guiu X., Amant F. et al. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol 2024;35(3):248–66. doi: 10.1016/j.annonc.2023.11.015
  5. Pignata S., Cecere S.C., Du Bois A. et al. Treatment of recurrent ovarian cancer. Ann Oncol 2017;28(suppl_8):viii51–6. doi: 10.1093/annonc/mdx441
  6. Miras I., Estévez-García P., Muñoz-Galván S. Clinical and molecular features of platinum resistance in ovarian cancer. Crit Rev Oncol Hematol 2024;201:104434. doi: 10.1016/j.critrevonc.2024.104434
  7. Havasi A., Cainap S.S., Havasi A.T., Cainap C. Ovarian cancer – insights into platinum resistance and overcoming it. Medicina (Kaunas) 2023;59(3):544. doi: 10.3390/medicina59030544
  8. Baert T., Ferrero A., Sehouli J. et al. The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol 2021;32(6):710–25. doi: 10.1016/j.annonc.2021.02.015
  9. Monk B.J., Herzog T.J., Tewari K.S. Evolution of chemosensitivity and resistance assays as predictors of clinical outcomes in epithelial ovarian cancer patients. Curr Pharm Des 2016;22(30):4717–28. doi: 10.2174/1381612822666160505114326
  10. Имянитов Е.Н. Принципы индивидуализации противоопухолевой терапии. Практическая онкология 2013;14(4):187–94. Imyanitov E.N. Principles of individualization of antitumor therapy. Prakticheskaya onkologiya = Practical Oncology 2013;14(4):187–94.
  11. Kirsanov K.I., Kuzin K.A., Fetisov T.I. et al. Methodological approaches to the determination of chemoresistance of human cancer cells to anti-cancer drugs. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2020;19(3):122–36. (In Russ.). doi: 10.21294/1814-4861-2020-19-3-122-136
  12. Singh T., Neal A.S., Moatamed N.A., Memarzadeh S. Exploring the potential of drug response assays for precision medicine in ovarian cancer. Int J Mol Sci 2021; 22(1):305. doi: 10.3390/ijms22010305
  13. Blom K., Nygren P., Larsson R., Andersson C.R. Predictive value of ex vivo chemosensitivity assays for individualized cancer chemotherapy: a meta-analysis. SLAS Technol 2017;22(3):306–14. doi: 10.1177/2472630316686297
  14. Maru Y., Hippo Y. Current status of patient-derived ovarian cancer models. Cells May 2019;8(5):505. doi: 10.3390/cells8050505
  15. Blumenthal R.D. An overview of chemosensitivity testing. Methods Molecul Med 2005:110:3–18. doi: 10.1385/1-59259-869-2:003
  16. Grendys E.C., Florica J.V., Orr J.W. et al. Overview of a chemoresponse assay in ovarian cancer. Clin Transl Oncol 2014;16(9):761–9. doi: 10.1007/s12094-014-1192-8
  17. Konecny G., Crohns C., Pegram M. et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000;77(2):258–63. doi: 10.1006/gyno.2000.5728
  18. Kurbacher C.M., Cree I.A. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med 2005;2005;110:101–20. doi: 10.1385/1-59259-869-2:101
  19. Andreotti P.E., Cree I.A., Kurbacher C.M. et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995;15;55(22):5276–82.
  20. Cortesi M., Warton K., Ford C.E. Beyond 2D cell cultures: how 3D models are changing the in vitro study of ovarian cancer and how to make the most of them. Peer J 29;12:e17603. doi: 10.7717/peerj.17603
  21. Denry Sato J., Kan M. Media for culture of mammalian cells. Curr Protoc Cell Biol. 2001;Chapter 1:Unit 1.2. doi: 10.1002/0471143030.cb0102s00
  22. Neubauer H., Stefanova M., Solomyer E. et al. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res 2008;28(2A):949–56.
  23. Nanki Y., Chiyoda T., Hirasawa A. et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci Rep 2020;10(1):12581. doi: 10.1038/s41598-020-69488-9
  24. Rodríguez-Corrales J., Josan J.S. Resazurin live cell assay: Setup and fine-tuning for reliable cytotoxicity results. Methods Mol Biol 2017;1647:207–219. doi: 10.1007/978-1-4939-7201-2_14
  25. Gong X., Liang Z., Yang Y. et al. A resazurin-based, nondestructive assay for monitoring cell proliferation during a scaffold-based 3D culture process. Regen Biomater 2020;7(3):271–81. doi: 10.1093/rb/rbaa002

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.